On May 30, Sinovac Holding Biology Co., Ltd. held a press conference to introduce relevant information about Sinovac's winning the bid for the vaccine project in Türkiye. It is reported that on May 24 local time in Türkiye, after fierce international competition, KeyVac, a joint venture invested by Sinovac in Türkiye, won the bid for the long-term supply project of hepatitis A and varicella vaccine in Türkiye. This bid means that SINOVAC Sinovac's vaccine products, services and technical capabilities have been recognized and trusted by Türkiye's government and people, which will greatly meet Türkiye's long-term needs for vaccines. Yang Guang, chief commercial officer of SINOVAC Science and Technology, said that the success of the vaccine project in Türkiye is not only an important step for SINOVAC Science and Technology to accelerate international cooperation, but also an important milestone for Chinese vaccine enterprises to carry forward the past and open up a new era for Chinese vaccines. Since 2013, SINOVAC Sinovac has actively participated in the bidding of hepatitis A vaccine in Türkiye, and explored local production cooperation. SINOVAC Sinovac will supply COVID-19 vaccine, hepatitis A vaccine, influenza vaccine and varicella vaccine to Türkiye in succession from 2020, with a total of nearly 94 million doses. The witness of the achievements of China Turkey cooperation in the field of public health and health made many governments realize that it is extremely important to have local production and supply capacity of vaccines as strategic materials during the outbreak of the COVID-19 epidemic. In this context, SINOVAC Kexing and Türkiye's local partner Alag z Holding Company jointly invested in the establishment of a joint venture KeyVac in October 2021. The total investment of KeyVac vaccine production base is 100 million US dollars, with an annual production capacity of 30 million doses of vaccines. Since Türkiye implements high EU standards, KeyVac production workshops and laboratories are designed and built in accordance with WHO and EU standards, and the whole chain of production, quality control and transportation has reached the international leading level. The factory has obtained the GMP certification in Türkiye in October 2023. The KeyVac factory and the successful cooperation in this bid are witnesses to the achievements of cooperation in the field of public health and wellness between China and Turkey. During the COVID-19 epidemic, President Erdogan of Türkiye took the lead in vaccinating the Kexing COVID-19 vaccine to encourage citizens to actively vaccinate and prevent and control the epidemic. On October 31, 2023, on the occasion of celebrating the 100th anniversary of Türkiye's founding, President Erdogan attended the KeyVac vaccine production workshop launch ceremony and delivered a speech. He said, "The COVID-19 has shown us the importance of vaccine production capacity. With the launch of the workshop, Türkiye will become a country that can produce vaccines with the highest standards. It is hoped that this highly strategic vaccine factory can benefit Ankara, Türkiye and the Turkish people." To provide impetus for the post epidemic global economic recovery, Chinese vaccine enterprises will deepen the "the Belt and Road" cooperation, accelerate international cooperation and international layout, and will work with other Chinese biomedical enterprises to promote the post epidemic global economic recovery. Provide power. SINOVAC Kexing has always adhered to and practiced the mission of "providing vaccines for eliminating human diseases", and has been deeply engaged in the field of vaccines for 23 years. The success of the Türkiye vaccine project is just a microcosm of the international cooperation of Chinese biomedical enterprises. In fact, long before the COVID-19 epidemic, SINOVAC has conducted extensive mutually beneficial cooperation in multiple countries. As of now, the company has supplied multiple types of vaccines to more than 80 countries and regions. In addition to the COVID-19 vaccine, SINOVAC also has 12 international quality vaccines, including hepatitis A, chickenpox, influenza, etc. Among them, 7 vaccine products have been registered in 37 countries. It is worth mentioning that there are currently 7 enterprises in China that have pre certified vaccine products from the World Health Organization, two of which are under SINOVAC's umbrella. SINOVAC not only has close commercial cooperation with other countries, but its industrial internationalization layout is also accelerating. The company has carried out diversified cooperation with numerous partners in Latin America, Asia, and Africa, from product supply, clinical research to industrial construction. The current world economic growth still faces many challenges, and the biopharmaceutical industry has the characteristic of not being affected by economic cycles, which can play a unique role in driving global economic growth. With innovative research and development and industrial development as the dual engines, we are working together to create a new era of Chinese vaccines. Chinese vaccine companies are working together to create a new era of Chinese vaccines with innovative research and development and industrial development as the dual engines. At present, Chinese biopharmaceutical enterprises represented by SINOVAC are actively expanding into the innovative pharmaceutical field while expanding internationally. SINOVAC has established a joint research institute, focusing on innovative research and development, and early development of innovative biopharmaceuticals in fields such as infectious diseases and chronic diseases. Not long ago, SINOVAC has invested in a domestic biopharmaceutical enterprise, Xingmeng Biotechnology, which focuses on the development of monoclonal antibodies in the fields of infectious diseases, malignant tumors, and autoimmune diseases. Xingmeng Biotechnology has established a complete industrial chain of related products and a rich pipeline of products under research, including multiple innovative monoclonal antibody drugs and biologically similar drugs. Investing in Xingmeng Biotechnology marks SINOVAC's entry into a broader new field of biopharmaceuticals. In addition, SINOVAC is still the contracting unit for the construction of the BRICS Vaccine Research and Development China Center. In the past few years, SINOVAC has conducted practical cooperation with partners from BRICS countries such as Brazil and South Africa in vaccine joint research and development, collaborative production, and other fields, achieving multiple important results. In recent years, SINOVAC has fully opened up international cooperation and accelerated its international layout, while also continuously investing in the forefront of biopharmaceuticals. future, SINOVAC will continue to expand in various fields such as monoclonal antibody drugs, cell therapy, and gene therapy through independent development, external investment, cooperation, and other means. It will not only use vaccines, but also more high-quality biopharmaceutical products to meet global disease prevention and control needs, helping to improve global health and well-being. (Lai Xin She)